Steven Cohen Immunome Inc. Transaction History

Point72 Asset Management, L.P.

$51 Billion
Q3 2025

A detailed history of Steven Cohen (Point72 Asset Management, L.P.) transactions in Immunome Inc. stock. As of the latest transaction made, Point72 Asset Management, L.P. holds 4,824,504 shares of IMNM stock, worth $82.7 Million. This represents 0.11% of its overall portfolio holdings.

Number of Shares

4,824,504

Previous 4,685,803 2.96%

Holding current value

$82.7 Million

Previous $43.6 Million 28.32%

% of portfolio

0.11%

Previous 0.1%

10 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2025 Nov 14, 2025	BUY	$8.4 - $11.59 $1.17 Million - $1.61 Million	138,701 Added 2.96%	4,824,504 $55.9 Million
Q2 2025 Aug 14, 2025	BUY	$5.56 - $9.79 $1.81 Million - $3.18 Million	325,128 Added 7.46%	4,685,803 $43.6 Million
Q1 2025 May 15, 2025	BUY	$6.73 - $11.83 $24.7 Million - $43.4 Million	3,671,885 Added 533.09%	4,360,675 $29.3 Million
Q4 2024 Feb 14, 2025	BUY	$9.11 - $14.53 $1.99 Million - $3.17 Million	218,143 Added 46.35%	688,790 $7.07 Million
Q3 2024 Nov 14, 2024	BUY	$11.7 - $16.51 $1 Million - $1.41 Million	85,580 Added 22.22%	470,647 $6.88 Million
Q2 2024 Aug 14, 2024	SELL	$11.54 - $22.11 $14.5 Million - $27.8 Million	-1,256,833 Reduced 76.55%	385,067 $4.66 Million
Q1 2024 May 15, 2024	BUY	$11.01 - $27.34 $10.6 Million - $26.2 Million	959,281 Added 140.53%	1,641,900 $40.5 Million
Q4 2023 Feb 14, 2024	BUY	$7.3 - $10.73 $997,910 - $1.47 Million	136,700 Added 25.04%	682,619 $7.3 Million
Q3 2023 Nov 14, 2023	BUY	$6.17 - $9.16 $788,476 - $1.17 Million	127,792 Added 30.56%	545,919 $4.56 Million
Q2 2023 Aug 14, 2023	BUY	$4.7 - $7.91 $1.97 Million - $3.31 Million	418,127 New	418,127 $3.31 Million

Others Institutions Holding IMNM

# of Institutions

166

Shares Held

71.5M

Call Options Held

325K

Put Options Held

4.31M

View Full List

About Immunome Inc.

Ticker IMNM
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 12,127,400
Market Cap $208M
Description
Immunome, Inc., a biopharmaceutical company, discovers and develops antibody therapeutics for oncology and infectious disease. The company's lead oncology program includes IMM-ONC-01, which targets IL-38 tumor-derived immune checkpoint capable of promoting evasion of the immune system. It also develops IMM-BCP-01, an antibody cocktail product ca...

More about IMNM

Track Steven Cohen's Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Point72 Asset Management, L.P., based on Form 13F filings with the SEC.

News

Stay updated on Point72 Asset Management, L.P. and Steven Cohen with notifications on news.

Account